Quinolone resistance in Salmonella spp. is usually attributed to both active efflux and mutations leading to modification of the target enzymes DNA gyrase and topoisomerase IV. Here, we investigated the presence of mutations in the efflux regulatory genes of fluoroquinolone-and multidrug-resistant mutants of Salmonella enterica serovar Typhimurium (S. Typhimurium) selected in vitro with enrofloxacin that both carried a mutation in the target gene gyrA and overproduced the AcrAB efflux pump. No mutations were detected in the global regulatory loci marRAB and soxRS for the four strains studied. A mutation in acrR, the local repressor of acrAB, was found for two ciprofloxacin-resistant selected-mutants, leading to duplication of amino acids Ile75 and Glu76. Complementation experiments with wild-type acrR showed that the mutation identified in acrR partially contributed to the increase in resistance levels to several unrelated antibiotics. The acrR mutation also contributed to acrAB overexpression as shown by RT-PCR. Thus, this study underlines the role of an acrR mutation, in addition to the mutation in gyrA, in the fluoroquinolone and multidrug resistance phenotype of S. Typhimurium mutants, through overexpression of acrAB.
Introduction
Fluoroquinolones (FQ), together with cephalosporins, are the treatment of choice for non-typhoid salmonellosis, as stable resistance to the most common antibiotic families (ampicillin, chloramphenicol, streptomycin, sulfonamides, and tetracycline) has developed during the 1990s with the epidemic Salmonella enterica serovar Typhimurium phage type DT104 (S. Typhimurium DT104) [1] . Emerging resistance to FQs in Salmonella spp. has been reported both in human and animal cases, and is thus threatening to become a serious public health problem [2, 3] .
In Salmonella spp., quinolone resistance has been attributed to point mutations in the gyrA gene coding for the A subunit of DNA gyrase, whose complex with DNA is the primary target of quinolones. These mutations cluster in a region termed the quinolone resistance-determining region (QRDR). Amino acid changes at Ser83 (to Phe, Tyr, or Ala) or at Asp87 (to Gly, Asn, or Tyr) are the most frequently observed in nalidixic acid-resistant strains [2, 3] . Double mutations at both residues 83 and 87 have been identified in clinical isolates of S. Typhimurium DT204 showing high-level resistance to FQs, together with one mutation leading to amino acid change Ser464Phe in the QRDR of gyrB encoding the B subunit of DNA gyrase. More recently, these high-level FQ-resistant isolates have been shown to carry a mutation leading to amino acid change Ser80-Ile in the QRDR of parC coding for the ParC subunit of topoisomerase IV, the secondary target of quinolones [4] [5] [6] [7] [8] [9] .
FQ resistance in S. Typhimurium has also been attributed to active efflux mechanisms [2, 3, 10, 11] , and we have recently reported participation of the AcrABTolC efflux system as an important mechanism of high-level resistance to FQs in S. Typhimurium DT204 [4, 5] . High-level resistance to FQs in Salmonella is thus essentially explained by the combination of two major resistance mechanisms, i.e., multiple target gene mutations and active efflux [4] .
Expression of acrAB, encoding the major AcrAB efflux pump, is subject to multiple levels of regulation. In Escherichia coli it is modulated at the lowest level by the local repressor AcrR [12] . At a more global level, acrAB expression is modulated by stress conditions and by global regulators like MarA, SoxS or Rob [13, 14] . The acrAB locus is indeed part of the mar, sox and rob regulon(s) of E. coli, whose activation confers a low level of resistance to a wide range of antimicrobial agents and organic solvents [13] . Proteins encoded by the mar locus include the transcriptional activator MarA, its local repressor MarR, and two proteins with unknown functions, MarB and MarC. MarR negatively regulates expression of marRAB by binding to the marO operator region [13, 15] . Proteins encoded by the soxRS locus include the transcriptional activator SoxS, and a protein, SoxR, whose oxidized form can activate soxS expression [14] .
Whilst these regulator systems have been well studied in E. coli, less is known about them in Salmonella spp. We investigated in this study whether the presence of mutations in regulatory regions like acrR, marRAB or soxRS, in addition to target gene mutations (gyrA), could participate in the FQ and multidrug resistance phenotype of S. Typhimurium mutants selected in vitro with enrofloxacin [16] . These mutants were previously shown to overproduce the periplasmic AcrA protein of the AcrAB-TolC efflux system [5, 10] .
Materials and methods
The strains used in this study are quinolone-susceptible S. Typhimurium strain BN18, isolated in France from a pigeon, and in vitro-selected quinolone-resistant mutants BN18/21, BN18/41, and BN18/71 derived from this strain and characterized previously (Table 1 ) [5, 10, 16] .
Identification of mutations in the acrR, soxRS, and marRAB regions was performed by PCR and nucleotide sequencing (Fig. 1) . PCR was performed using primers listed in Table 2 and conditions as follows: 5 min at 94°C
, 30 cycles of (1 min at 94°C, 1 min at annealing temperature, 1 min 30 s at 72°C), and a final 10 min at 72°C
. Nucleotide sequencing was performed by Genome Express (Meylan, France) and analysed with the Vector NTI Suite 7 program (Informax, Inc., Bethesda, Md.).
The acrR-complementing plasmid was constructed as follows: the 992-bp acrR PCR fragment from the genomic DNA of strain BN18 was digested with EcoRI and BamHI (Promega, Madison, WI), purified, and ligated into the EcoRI-and BamHI-digested broad-host-range plasmid vector pBR1MCS2 [17] . The resulting recombinant plasmid (pBRacrR18) was then electroporated into E. coli TG1 cells, with selection on LB agar plates containing 50 lg/ml of kanamycin (Fluka, France). The cloned wild-type acrR gene was transferred into BN18/ 21, BN18/41, and BN18/71 mutants by electroporation of plasmid pBRacrR18. The effect of complementation with the wild-type acrR gene was examined by determin- , and tetracycline (Fluka, France) were determined by the standard agar doubling dilution method as described previously [5] .
RT-PCR was used to assess expression of acrB. Overnight cultures were diluted 1/100 in LB medium and grown to the mid-logarithmic phase (OD 600 nm = 0.5) at 37°C with shaking. 4 ml Aliquots of cultures were pelleted by centrifugation at 14,000g for 10 min, and mixed with 1 ml of Trizol (Invitrogen, Cergy-Pontoise, France), a reagent that maintains the integrity of the RNA while disrupting cells and dissolving cell components. Homogenized samples were incubated for 5 min at 30°C, shaken with 0.2 ml of chloroform and then centrifuged for 15 min at 12,000g. RNA, which remains in the aqueous phase, was precipitated with 0.5 ml of isopropyl alcohol. After 10 min of incubation at room temperature, samples were centrifuged for 10 min at 12,000g. The RNA pellet was washed with 1 ml of and then 15 min at 70°C. Generated cDNA was incubated 20 min at 37°C with 1 ll of RNaseA (500 lg/ml, Qbiogene, France) and stored at À20°C until use. Differences in acrB gene expression were estimated by PCR using target specific primers acrBP1 and acrBP2 (Table 2) . A sample of 1 ll of total cDNA was amplified in a 20 ll volume reaction containing 0.5 lM of each primer, 250 lM of dNTPs, 1· of Taq Buffer and 0.5 U of Taq DNA polymerase. Amplifications were performed with an initial denaturation step of 3 min at 95°C
, followed by 35 cycles of (20 s at 95°C, 20 s at the annealing temperature and 20 s at 72°C). Constitutive expression of gyrB assessed in the same cDNA preparation was used as a control, using primers gyrBP1 and gyrBP2 (Table 2) . PCR products were detected on 1.5% agarose gel containing ethidium bromide and the level of gene derepression was estimated by comparison of the band intensities relative to twofold serial dilutions of cDNAs.
Results and discussion
The presence of mutations in the regulatory loci acrR, marRAB and soxRS was assessed in S. Typhimurium mutants that were selected with enrofloxacin and whose phenotype of resistance to FQs could not be explained only by mutations in the target gene gyrA [10, 16] . These mutants, BN18/21, BN18/41 and BN18/71, were all derived from fully susceptible strain BN18 with, respectively, 2, 4, and 7 steps of selection with enrofloxacin [16] . Strain BN18/21 exhibited a decreased susceptibility to ciprofloxacin with an MIC value of 0.125 lg/ml compared to 0.03 lg/ml in the parent strain whereas strains BN18/41 and BN18/71 showed ciprofloxacin resistance with MICs of 2 and 8 lg/ml, respectively (Table 1) . Mutants BN18/41 and BN18/71 both carried a mutation in gyrA leading to amino acid change Gly81Cys. No mutations were found in the QRDRs of their gyrB, parC or parE genes [5, 10, 16] . In addition, BN18/21, BN18/41 and BN18/71 exhibited active efflux mechanisms and showed overproduction of AcrA protein relative to their parental strain BN18 in previous immunoblotting assays [5, 10] .
In E. coli, enhanced efflux due to overexpression of acrAB in mutants that displayed a Mar (multiple antibiotic resistance) phenotype has been attributed to mutations in marR, the repressor of the marRAB operon [13] . Conversely, Salmonella Mar mutants produced by passage with tetracycline or chloramphenicol generally lacked mutations in the marOR region [13] . However, mutations in the soxRS locus have been found in FQ-resistant strains of both E. coli [18, 19] and S. enterica [20] .
In this study, no mutations were detected in the global regulatory regions marRAB and soxRS for the four strains studied. However, strains BN18/41 and BN18/71 were both found to carry a mutation in acrR, i.e., a 6-bp duplication of nucleotides 223-228 leading to the duplication of amino acids Ile75 and Glu76 (Fig. 1) . The AcrR protein is known in E. coli to repress transcription of the acrAB operon [12] . The mutation we identified within the acrR gene could thus result in the production of a less active AcrR repressor protein which would explain overexpression of acrAB and the consequent multidrug resistance phenotype of mutant strains BN18/41 and BN18/71 [5, 10, 16] . A number of mutations in the acrR local repressor of acrAB have also been described in clinical E. coli strains and also resulted in enhanced expression of acrAB and increased FQ resistance [21] [22] [23] . Mutations were located at random throughout the repressor gene and in every case, the wild-type AcrR supplanted the host mutant AcrR [23] . A mutation in acrR was also recently identified among pig herd ciprofloxacin-resistant S. Cholerasuis isolates that in addition had two mutations in gyrA and one in parC [24] .
In order to determine the contribution of the acrR mutation in the multidrug resistance phenotype of BN18/41 and BN18/71, complementation experiments with a plasmid-borne wild type acrR gene were performed. The complemented mutants showed a fourfold decrease in their resistance levels to flumequine, marbofloxacin, enrofloxacin, ciprofloxacin, florfenicol, chloramphenicol and tetracycline (Table 1) . Wild-type acrR thus partially contributed to the decrease in resistance levels to several unrelated antibiotics. In addition, RT-PCR experiments were used to determine the contribution of the acrR mutation in acrB overexpression. Whereas acrB was overexpressed in quinolone-resistant mutants BN18/21, BN18/41 and BN18/71 compared to susceptible strain BN18, wild-type acrR complemented strains all showed the same decreased acrB expression level in agarose gels, which was comparable to that of susceptible strain BN18 (Fig. 2) . Interpretation of these data was correlated by reference to a negative control in RT-PCR experiments, i.e., gene gyrB whose transcription was not affected by the treatments undertaken in this study. Indeed, the same band intensity relative to gyrB transcription was observed for the eight strains tested (Fig. 2) . The decreased acrAB expression levels (about 5 times) correlated well with the decreased resistance levels to the antibiotics tested observed in wild-type acrR complemented strains BN18/41 and BN18/71. This was not the case for mutant BN18/21, for which transformation with a plasmid encoding acrR had little effect upon resistance to most quinolone antibiotics. This indicates that probably another unidentified locus apart from mar and sox must be implicated in the up-regulation of acrAB and the multidrug resistance phenotype of this strain, and this must logically also be true for strains BN18/41 and BN18/71. The restoration of a basal acrAB expression level observed in the acrR complemented mutant of BN18/21 remains yet unclear, and could be due to a dominant effect of AcrR upon this unidentified regulator.
The multidrug resistance phenotype of these S. Typhimurium FQ-resistant strains was previously shown to involve active efflux prior to gyrA mutations [10] . Alterations in the outer membrane protein and lipopolysaccharide profiles possibly resulting in decreased permeability were also described for these mutants [10] . This study presents evidence for the role of an acrR mutation in the up-regulation of the efflux pump AcrAB and therefore in the multidrug resistance phenotype of S. Typhimurium. Previous findings support the fact that presumably the acrR complementing plasmid failed to fully complement the mutant phenotypes in BN18/41 and BN18/71 due to the presence of the secondary gyrA G81C mutation. The particular case of strain BN18/21 suggested that another unidentified regulator locus, apart from acrR, mar, and sox, could also be implicated. Taken together, these studies underline the potential synergic contribution of mutations affecting the outer membrane permeability, affecting the gyrase encoding gene gyrA, and affecting AcrABmediated efflux mechanism in the FQ and multidrug resistance phenotype of S. Typhimurium.
